The Skinny on Diabetes Drugs – a helpful little summary on current treatments from the Motley Fool.
Beaker’s Blog tells us that only 4 life sciences companies really matter. Who are they, and why?
Astellas continues to pursue CV Therapeutics after takeover bid rejected.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Leave a Reply